Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
暂无分享,去创建一个
W. Hiddemann | K. Spiekermann | S. Schnittger | J. Ellwart | Ksenia Bagrintseva | R. Schwab | T. Kohl | Sabine Eichenlaub | Tobias M. Kohl